SKYE Stock Risk & Deep Value Analysis
Skye Bioscience Inc
Healthcare • Biotechnology
DVR Score
out of 10
What You Need to Know About SKYE Stock
We analyzed Skye Bioscience Inc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran SKYE through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Aggressive. Here's what we found.
SKYE Risk Analysis & Red Flags
What Could Go Wrong
The company's extremely low market cap ($20M) and critical lack of significant cash reserves mean it faces an existential financial crisis. Failure to secure substantial funding for Phase 3 trials, likely leading to severe dilution, will halt drug development and could result in bankruptcy or delisting.
Risk Matrix
Overall
Aggressive
Financial
High
Market
Medium
Competitive
Medium
Execution
High
Regulatory
High
Red Flags
- ⚠
Extremely low market capitalization ($20M)
- ⚠
Recent 1-for-20 reverse stock split (March 2026)
- ⚠
High cash burn rate with no revenue generation
- ⚠
Urgent need for hundreds of millions of dollars to fund Phase 3 trials
Upcoming Risk Events
- 📅
Failure to secure sufficient Phase 3 funding (ongoing)
- 📅
Negative or inconclusive Phase 3 trial results
- 📅
Increased competitive pressure from new glaucoma therapies
When to Reconsider
- 🚪
Failure to announce successful Phase 3 financing within the next 6-9 months
- 🚪
Significant negative updates on Phase 3 trial initiation or enrollment
- 🚪
Market capitalization consistently falling below $10M
Unlock SKYE Risk Analysis & Red Flags
Create a free account to see the full analysis
What Does Skye Bioscience Inc (SKYE) Do?
Sector
Healthcare
Industry
Biotechnology
Employees
16
Skye Bioscience, Inc., a clinical stage biopharmaceutical company, focuses on developing molecules that modulate G protein-coupled receptors (GPCRs) to treat obesity, overweight, and metabolic diseases. Its lead product candidate is nimacimab, a peripherally restricted negative allosteric modulating antibody targeting cannabinoid receptor 1, a key GPCR involved in metabolic regulation. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. The company is headquartered in San Diego, California.
Visit Skye Bioscience Inc WebsiteInvestment Thesis
Skye Bioscience offers an extremely high-risk, high-reward investment opportunity based on its novel cannabinoid-derived glaucoma therapy, SBI-100, which showed positive Phase 2a data. The bull case hinges on the company successfully securing significant non-dilutive or minimally dilutive funding for Phase 3 trials, achieving positive clinical outcomes, and ultimately gaining regulatory approval and commercializing SBI-100 in a large addressable market. The current distressed valuation offers significant upside if these hurdles are overcome.
Is SKYE Stock Undervalued?
Unlock the full AI analysis for SKYE
Get the complete DVR score, risk analysis, and more
Unlock the full report
Create a free account to see the DVR score, risk flags, and AI analysis.
SKYE Price Targets & Strategy
12-Month Target
$1.50
Bull Case
$3.00
Bear Case
$0.20
Valuation Basis
Based on projected market cap re-rating to ~$100M-$120M post-successful Phase 3 financing and initiation, diluted for expected capital raises.
Entry Strategy
Highly speculative entry. Consider dollar-cost averaging between $0.50-$0.60 if there is news of positive financing discussions or technical stabilization above $0.50.
Exit Strategy
Take 50% profit at $1.50, reassess on further clinical data. Stop loss at $0.30 if financial situation deteriorates or key funding milestones are missed.
Portfolio Allocation
0.5%-1% for aggressive risk tolerance only. This is a venture-style investment.
Price Targets & Strategy
Upgrade to Premium for price targets and entry/exit strategies
Does SKYE Have a Competitive Moat?
Sign in to unlockMoat Rating
🛡️ Narrow
Moat Trend
Stable
Moat Sources
1 Identified
The moat is primarily derived from intellectual property surrounding the novel cannabinoid-derived compound SBI-100 and initial clinical validation. Its durability is entirely dependent on successful completion of Phase 3 trials, regulatory approval, and sustained patent protection.
Moat Erosion Risks
- •Failure of SBI-100 in Phase 3 clinical trials
- •Emergence of superior or more cost-effective competitive therapies
- •Patent challenges or expiry reducing exclusivity
SKYE Competitive Moat Analysis
Sign up to see competitive advantages
SKYE Market Intelligence
Sentiment & Insider Activity
Social Sentiment
Bearish (due to reverse split and financial distress) with pockets of bullishness from long-term believers in the science.
Institutional Sentiment
Negative/Skeptical (due to high financial risk and early stage). No significant institutional upgrades/downgrades expected at this stage.
Insider Activity (Form 4)
No specific insider buying or selling reported in recent filings, indicating a neutral stance.
Options Flow
Normal options activity; limited volume reflecting the small market cap and speculative nature.
Earnings Intelligence
Next Earnings
Estimated late-May 2026 (for Q1 2026)
Surprise Probability
Low (as focus is on R&D pipeline and cash position, not revenue/profit surprises)
Historical Earnings Pattern
Stock price highly volatile around R&D updates and news related to financing or clinical milestones, rather than traditional earnings beats/misses.
Key Metrics to Watch
Competitive Position
Top Competitor
Aerie Pharmaceuticals (acquired by Alcon) for a sense of glaucoma drug development, though Skye's MOA is distinct.
Market Share Trend
Not applicable; pre-commercial stage.
Valuation vs Peers
Trading at a significant discount to established biotech peers with drugs in Phase 3 or commercialization, due to its distressed financial state and pre-revenue nature.
Competitive Advantages
- •Novel mechanism of action (cannabinoid-derived topical therapy for glaucoma)
- •Positive Phase 2a clinical data for SBI-100
- •Proprietary intellectual property protecting SBI-100
Market Intelligence
Get sentiment, earnings intel, and peer analysis with Premium
What Could Drive SKYE Stock Higher?
Near-Term (0-6 months)
- •Announcement of Phase 3 trial design and initiation (Q2/Q3 2026)
- •Securing significant Series A/B equivalent funding round for Phase 3 (H2 2026)
Medium-Term (6-18 months)
- •Updates on patient enrollment progress for Phase 3 trial (2027)
- •Potential strategic partnership or licensing deal for SBI-100 (2027)
Long-Term (18+ months)
- •Top-line Phase 3 data readout for SBI-100 (2028-2029)
- •Regulatory submission and potential approval for SBI-100 (2029-2030)
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
What's the Bull Case for SKYE?
- ✓
Announcement of substantial, non-crippling Phase 3 financing
- ✓
Positive updates on Phase 3 trial initiation and patient enrollment metrics
Bull Case Analysis
See what could go right with Premium
Competing with SKYE
See how Skye Bioscience Inc compares to related companies
| Company | Market Cap | DVR Score | P/E | Revenue | Profit Margin | Rev Growth | |
|---|---|---|---|---|---|---|---|
Skye Bioscience Inc SKYE | — | 5.5 | — | — | — | — | |
AbbVie Inc ABBV | $403.8B | 0.1 | 171.8 | — | — | — | Compare → |
Johnson & Johnson JNJ | — | 1.0 | — | — | — | — | Compare → |
Eli Lilly and Co LLY | $965.0B | 0.5 | 52.6 | — | — | — | Compare → |
Pfizer Inc PFE | $150.6B | 0.2 | 19.4 | $62.6B | 12.4% | -1.6% | Compare → |
UnitedHealth Group Inc UNH | $276.2B | 0.3 | 22.9 | $113.7B | 2.7% | 1181.0% | Compare → |
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
FAQ
What is the DVR Score for Skye Bioscience Inc (SKYE)?
As of March 29, 2026, Skye Bioscience Inc has a DVR Score of 5.5 out of 10, placing it in the "Proceed with Caution" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.
What ticker symbol does Skye Bioscience Inc use?
SKYE is the ticker symbol for Skye Bioscience Inc. The company trades on the NGM.
What is the risk level for SKYE stock?
Our analysis rates Skye Bioscience Inc's overall risk as Aggressive. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.
How often is the SKYE DVR analysis updated?
Our AI-powered analysis of Skye Bioscience Inc is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on March 29, 2026.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for SKYE (Skye Bioscience Inc) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.